Articles tagged with Cancer Medication
Researchers have discovered that over-activation of the c-Abl protein can shut down parkin's protective function, leading to a build-up of toxic proteins and neuron death. Inhibiting c-Abl with existing drugs like imatinib may provide a new treatment approach for Parkinson's disease.
A molecular imaging technique may help identify early response to treatment in cisplatin-resistant ovarian cancer, potentially reducing unnecessary side effects and offering more effective treatments. Researchers used a PET probe to monitor tumor growth in mice with human ovarian cancer.
Researchers discuss factors contributing to cancer disparities, including language barriers and lack of health literacy. Successful strategies include tailoring messages to specific audiences and promoting evidence-based programs like Body and Soul.
Researchers propose a new approach to combat cancer and autoimmune diseases by targeting the balance between NF-kB and p53 signaling pathways. This balance is believed to be a promising target for developing new drugs, with potential benefits including improved disease treatment outcomes.
A phase 3 trial shows cabazitaxel improves overall and progression-free survival in men with advanced multi-drug resistant prostate cancer. The medication was found to be effective in patients whose disease progressed after standard chemotherapy with docetaxel.
Researchers engineered E. coli bacteria to produce taxadiene, a precursor to the cancer drug Taxol, achieving 1,000 times more production than previous strains. The technique could bring down manufacturing costs and help discover new therapeutic compounds for cancer and other diseases.
USC professor Andrea Armani is developing a real-time nanolaser instrument to locate carcinogens and their induced changes in living cells. This technology aims to create personalized cancer drug delivery systems, potentially within 10-15 years.
Researchers have uncovered a key mechanism in which leukemia cells trigger a protective response when exposed to histone deacetylase inhibitors. By disrupting this pathway, the cancer-killing capacity of HDACIs can be increased dramatically.
The NIH Director's Transformative Research Projects (T-R01) award program provides funding for exceptionally innovative research ideas that have the potential for extraordinary impact. The program allows investigators to sidestep conventional stumbling blocks and propose daring ideas.
A recent study found that the majority of US adults lack sufficient information to make the best medical decisions. To address this issue, doctors need to help patients prepare better for health decisions. Key findings include the importance of informed consent and patient decision aids in ensuring patients' preferences are respected.
A new immunotherapy treatment has improved two-year survival rates for high-risk neuroblastoma patients by 20 percent compared to standard treatment. Researchers report a higher cure rate, but also more pain and toxic side effects.
A new clinical trial found that 96% of patients with intermediate-risk neuroblastoma survived for three years after receiving reduced chemotherapy doses. The study, led by Katherine Matthay at UCSF Benioff Children's Hospital, aimed to minimize the toxic effects of cancer drugs on young children.
A team of UNC scientists has received a $2,308,800 grant to develop targeted nano-particle technology for early detection and more effective treatments of pancreatic cancer. The goal is to design nanoscale metal-organic frameworks capable of carrying imaging and therapeutic cargoes or multiple drugs.
Researchers have found a new drug combination that enhances anti-tumor efficacy and protects the heart from damage caused by doxorubicin, a powerful anti-cancer drug. The combination of Viagra and doxorubicin significantly reduces tumor size in prostate cancer patients without harming healthy cells.
A Mayo Clinic collaboration identified four genetic variants on chromosome 14 associated with aromatase inhibitor-induced arthritis. These findings provide a new clue for identifying women at risk and developing treatments, allowing more women to take lifesaving breast cancer therapy.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development. This pathway, part of a global DNA damage response, turns off 136 genes that can promote aberrant cell division and cancer.
Scientists have developed a new form of methotrexate as nose drops to treat brain cancer, showing promise in bypassing the blood-brain barrier. In initial testing on laboratory rats with brain cancer, the nose drop drug reduced tumor weight by almost one-third compared to injectable treatment.
Researchers found that genes in a signaling network, not just individual molecules, contribute to resistance. Most genes were not mutated, but rather altered their function to evade treatment. The study's findings highlight the need for new therapeutic approaches targeting the complex interactions within cancer cell networks.
Researchers at Fox Chase Cancer Center identified over 60 proteins necessary for cancer cells to survive with EGFR inhibitors, demonstrating a two-hit strategy that increases tumor cell death. This approach will open the door for future therapies and has already led to two clinical trials testing innovative drug combinations.
A new study at Duke University Medical Center found that nearly 30% of Americans with voice problems have never received treatment, highlighting a need for better awareness and advocacy. The study also highlights the importance of early detection and personalized treatment plans to manage chronic conditions.
Researchers at Mayo Clinic found that pazopanib significantly decreased progression rate in patients with metastatic, rapidly progressive differentiated thyroid cancers. The median progression-free survival time was 11.7 months, with an overall survival rate of 81 percent at one year.
A phase 2 trial found that pazopanib, an antiangiogenetic drug, significantly improved outcomes for patients with advanced differentiated thyroid cancers. Approximately 49% of patients experienced a partial response, with two-thirds likely to have a lasting response over 1 year.
Research published online in journal Gut found that taking even a very low dose of regular aspirin (75 mg) can reduce the risk of developing bowel cancer. After one year, daily low-dose aspirin was associated with a 22% reduced risk of developing bowel cancer, which increased to 30% after five years.
Researchers at Washington University School of Medicine discovered a new drug target that can improve the effectiveness of radiation therapy for hard-to-treat cancers. The enzyme cytosolic phospholipase A2 (cPLA2) promotes tumor angiogenesis, enabling tumors to overcome radiation effects.
A multicenter trial found that childhood cancer survivors who took methylphenidate showed improved sustained attention and social skills, with benefits lasting a year after treatment. The study offers hope and reassurance for survivors and their families.
Researchers find a crucial protein involved in immune response also plays a role in T-cell acute lymphoblastic leukemia (T-ALL) progression. Suppressing the protein's activity eliminates leukemic cells, paving the way for potential new treatments.
A team of UC Davis scientists discovered a novel mechanism behind Vioxx's link to heart attacks and strokes, finding that the drug increases a regulatory lipid that contributes to cardiovascular events. The research may pave the way for safer coxibs for millions of arthritis patients.
Ipilimumab shows significant survival benefits in stage IV melanoma patients, with a median survival of 10 months. The FDA grants priority review status to this cancer treatment, providing new hope for those with devastating disease.
Researchers at the University of Illinois have identified a new target for cancer therapy in dogs and tested a compound that arrested tumor growth and induced partial remission. The study suggests that the treatment could be effective and safe, potentially adding to existing lymphoma treatments.
Researchers at Purdue University have developed a new type of pump for drug-delivery patches that uses arrays of microneedles to deliver a wider range of medications. The pump is activated by touch and can exert pressure to force drugs through the needles, with prototypes exerting pressures of up to 4.87 psi.
A new targeted therapy called PLX4032 has been linked to an 80% response rate in treating advanced melanoma. The treatment, which targets the BRAF protein, has shown significant tumor shrinkage and improved quality of life for some patients.
A phase 1 clinical trial showed that PLX4032 significantly shrinks tumors in over 80% of patients with metastatic melanoma and the mutated BRAF gene. The drug has also improved quality of life by reducing symptoms such as pain and fatigue within a week.
Researchers at Tel Aviv University have developed a nano-sized vehicle that can deliver chemotherapy drugs directly into cancer cells while avoiding interaction with healthy cells. This technology has the potential to increase the efficiency of chemotherapeutic treatments while reducing their debilitating side effects.
Researchers developed new 'stapled peptides' to block key cancer proteins, showing promise for treating cancer, diabetes, and other diseases. The advances could lead to a new generation of medicines, overcoming the shortcomings of previous drugs.
Researchers at the University of Minnesota have identified two FDA-approved drugs, decitabine and gemcitabine, which, when combined, may be an effective treatment for HIV. The drug combination forces the virus to mutate itself to death, a phenomenon dubbed 'lethal mutagenesis.'
Researchers have identified two effective treatments for neuroblastoma in mice using existing medications DECA-14 and rapamycin. The study used cancer stem cells directly isolated from children's tumors to test the drugs' efficacy without harming healthy cells.
A study by Yale University researchers found that a combination of four herbs reduced gastrointestinal side effects of chemotherapy in mice while increasing the effectiveness of cancer treatment. The herbal formula PHY906 enhanced anti-tumor activity and promoted intestinal cell regeneration.
Palliative care significantly improved the lives of lung cancer patients, extending their survival by an average of 11.6 months compared to those receiving standard care alone. Quality-of-life assessments also showed substantial improvement in the palliative care group.
A CSHL-led team found that increased IL-6 secretion can lead to decreased sensitivity to Tarceva, a targeted therapy for lung cancer. They also discovered that tumor cells with up-regulated TGF-β and increased IL-6 secretion were resistant to treatment independently of the EGFR pathway.
The study found that depleting SIK2 from ovarian cancers sensitized the cells to paclitaxel, making it more effective in stopping cancer growth. Levels of SIK2 protein are increased in approximately 30 percent of ovarian cancers and associated with poorer survival rates.
Researchers at VCU Massey Cancer Center have discovered a new link between chronic inflammation and cancer, highlighting the importance of sphingosine-1-phosphate (S1P) in regulating inflammation. S1P is found to be a missing cofactor required for TRAF2's activity, which controls inflammation and cancer.
A study by the University of Houston team suggests that higher exposure to estrogens may be connected to gallbladder cancer. The research found that eliminating estrogens prevents tumor development in a specific animal model, leading to potential new drugs and understanding individual risks.
Researchers at Beth Israel Deaconess Medical Center discovered that the MDM2 oncogene is regulated by a complex signaling pathway involving enzymes CKI and beta-TRCP1. This finding suggests a 'dimmer switch' control mechanism, which could lead to new drug targets for killing tumors.
Researchers have developed a way to deliver drugs directly to tumors using nanoparticles, reducing the risk of severe side effects. The new approach uses immune cells to target tumors, allowing for more effective cancer treatment.
The international community must prioritize cancer care as a global health issue, with stark disparities between low- and high-income countries. Implementing evidence-based interventions can prevent or ease suffering from many malignancies, reducing the gap in access to care.
Despite high burden of disease, many cancers are preventable or treatable with generic drugs, education, and training. Initiatives like vaccination against HPV and hepatitis B virus can significantly impact cancer mortality. GTF.CCC aims to support existing initiatives and improve health systems in LMICs.
Assistant Professor Annelise Nguyen receives $370,000 grant to study cell communication in cancer cells, potentially leading to enhanced drug treatments. Her work also has potential applications for colon and prostate cancers.
A study of over 80,000 patients in the UK found no significant association between oral bisphosphonate use and an increased risk of esophageal or gastric cancer. The analysis excluded patients with less than 6 months follow-up, resulting in 41,826 members in each group.
BGU Professor Ron N. Apte received the 2010 Samuel and Paula Elkeles Prize for Outstanding Scientist in the Field of Medicine. His research focuses on inflammation in malignant processes, with a major emphasis on IL-1-mediated inflammation in tumor invasiveness and metastasis.
Scientists create a new system that utilizes porous nanomaterials driven by a magnetic core to release drugs inside living cancer cells, improving targeted drug delivery and imaging in cancer treatment. The system has the potential to deliver anti-cancer drugs only to cancer cells while leaving healthy cells unharmed.
The UK government's £50 million emergency cancer fund is under fire for its potential to favor patients based on geographical location rather than medical need. The Lancet Editorial argues that this policy undermines the principles of evidence-based medicine and rational healthcare resource allocation.
The University of Louisville has received a $3.15 million grant from the Helmsley Charitable Trust to support its cancer research program in Owensboro. The funding will be used to create new faculty positions and expand the research program, with a focus on developing plant-based pharmaceuticals.
A peptide derived from bee venom can deliver liposomes bearing drugs or diagnostic dyes to specific cells or tissues, improving the effectiveness of cancer treatment. This 'smart bomb' technology may help design personalized treatment regimens that can selectively target tumors and other diseases.
Researchers have made a groundbreaking discovery that challenges scientists' understanding of programmed cell death and its role in tumour formation. The study found that the body's natural cell-suicide program can fuel tumour development under certain conditions.
Researchers at Rensselaer Polytechnic Institute are developing new technology to push drugs through the blood-brain barrier, directly targeting brain tumors. The goal is to deliver treatments for diffuse malignant glioma, a lethal type of brain cancer with no cure.
A UNC physician authored an editorial on a cost-effectiveness study comparing colonoscopy and computed tomographic colonography (CTC) for colon cancer screening. The analysis concluded that CTC is not cost-effective compared to colonoscopy if reimbursed at the same rate.
Researchers identified a way to predict which cancer patients will respond to everolimus, a treatment targeting the protein mTOR. The presence of KRAS gene mutations is associated with lack of response to treatment, suggesting that looking for PIK3CA and KRAS mutations can help predict patient outcomes.
A study of 601 childhood cancer survivors found that 27% had abnormal cardiac function, with no evidence that sex or certain treatments were risk factors. The study highlights the need for continued monitoring of these patients to prevent further deterioration of cardiac function.
Researchers have developed a new drug that targets peripheral CB1 cannabinoid receptors to improve cardiometabolic risk in mouse models of obesity. The drug inhibits the same protein as rimonabant, but without neurological side effects. This approach may reduce health risks associated with obesity and type 2 diabetes.
Researchers discovered a non-human sialic acid sugar in biotech drugs that can provoke a strong immune response in some individuals, worsening chronic inflammation. A simple modification to the drug-making process could solve this problem by adding human sialic acid.